Contributions
Abstract: EP1819
Type: ePoster
Abstract Category: Therapy - symptomatic - 33 Treatment of specific symptoms
Background: MS patients have an increased incidence of headaches. Headache in MS commonly could be both presented as episodic or chronic migraine. Chronic migraine occurring on more than 15 days per month for at least 3 months and a daily duration of at least 4 hours, is considered with possible efficacy of botulinum toxin A.
FDA approved botulinum as a treatment for muscle relaxation in MS patients in 2010 so its utilization considered to be safe. We used botulinum A in a cohort of MS patients with chronic and intractable migraine.
Method: 302 out of 1200 patients with definite MS taking standard MS treatment, complained headache fulfilling migraine criteria.25 out of 302 patients didn't respond to the common oral migraine treatment defined as below 30% response. We injected botulinum toxin A in 31 anatomical standard points on skull, reporting frequency, intensity, duration and medication rescue.
Results: All the cases were female with the mean age of 30.20, a mean disease duration of 55.72 months and mean EDSS of 1.5. Mean migraine frequency was 4.48 per week, intensity 78.57% out of 100 and duration of 9.96 hours. Standard oral migraine treatment response rate in these 25 patients was 21.78%.
Before injection the mean migraine frequency was 6.28 per week, intensity 94.8% and duration 10.36 hours. After injection the mean frequency 1.16 per week, the mean intensity 26 out of 100, and the duration was 2.24 hours. The mean Botulinum dosage was 1.36, equal to680 unit.
Conclusion: Botulinum toxin A should be considered a safe and effective treatment in MS patients with intractable chronic migraine.
Keywords: MS, Botulinum toxin, intractable chronic migraine, headache
Disclosure: No conflict of interest
Abstract: EP1819
Type: ePoster
Abstract Category: Therapy - symptomatic - 33 Treatment of specific symptoms
Background: MS patients have an increased incidence of headaches. Headache in MS commonly could be both presented as episodic or chronic migraine. Chronic migraine occurring on more than 15 days per month for at least 3 months and a daily duration of at least 4 hours, is considered with possible efficacy of botulinum toxin A.
FDA approved botulinum as a treatment for muscle relaxation in MS patients in 2010 so its utilization considered to be safe. We used botulinum A in a cohort of MS patients with chronic and intractable migraine.
Method: 302 out of 1200 patients with definite MS taking standard MS treatment, complained headache fulfilling migraine criteria.25 out of 302 patients didn't respond to the common oral migraine treatment defined as below 30% response. We injected botulinum toxin A in 31 anatomical standard points on skull, reporting frequency, intensity, duration and medication rescue.
Results: All the cases were female with the mean age of 30.20, a mean disease duration of 55.72 months and mean EDSS of 1.5. Mean migraine frequency was 4.48 per week, intensity 78.57% out of 100 and duration of 9.96 hours. Standard oral migraine treatment response rate in these 25 patients was 21.78%.
Before injection the mean migraine frequency was 6.28 per week, intensity 94.8% and duration 10.36 hours. After injection the mean frequency 1.16 per week, the mean intensity 26 out of 100, and the duration was 2.24 hours. The mean Botulinum dosage was 1.36, equal to680 unit.
Conclusion: Botulinum toxin A should be considered a safe and effective treatment in MS patients with intractable chronic migraine.
Keywords: MS, Botulinum toxin, intractable chronic migraine, headache
Disclosure: No conflict of interest